ABSTRACT
Introduction
Tricuspid regurgitation has been increasingly recognized as a clinically relevant entity with a long-term prognostic impact on quality of life and survival. Despite this, there are still some unmet clinical needs regarding the management of tricuspid regurgitation that require further investigation.
Areas covered
This review addresses current evidence for the treatment of tricuspid regurgitation, focusing primarily on new catheter-based technologies. In addition, we discuss recent registries and clinical trial outcomes.
Expert opinion
A multimodality and multiparametric integrative approach has been preconized to assess tricuspid regurgitation mechanism and severity, and new technologies have been developed to address the main causative factors of tricuspid regurgitation. Matching the right device to the right patient and deciding when is the best time for intervention are major challenges in the management of tricuspid regurgitation.
Article highlights
Tricuspid regurgitation has been increasingly recognized as a clinically relevant condition
Tricuspid regurgitation has a major impact on quality of life and survival
Transcatheter tricuspid valve intervention offers a less invasive alternative approach for patients with severe symptomatic tricuspid regurgitation
There are still some unmet needs in the management of tricuspid regurgitation that deserve further investigation
Declaration of interest
AP Tagliari has received a research grant from CAPES – Brazil (Finance Code 001), and has received a speaking fee from Biotronik.
M Taramasso has been a consultant or the recipient of consultancy fees from Abbott, Edwards Lifesciences, Boston Scientific, Shenqi Medical, CoreMedic, 4tech, Simulands, MTEx, Cardiovalve, and MEDIRA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.